Last week, the FDA approved both Valeant's Xifaxan and Actavis' new Viberzi to treat IBS-D. And now, the market will get to watch what Bernstein analyst Ronny Gal deemed an "interesting test" of two company approaches as the pair competes for uptake.
Summer music festival goers may see a new face this year among the beer and souvenir tents. Pedialyte, Abbott Laboratories' electrolyte drink for sick kids, is joining the summer fun circuit to hand out samples as an antidote for overindulgence.
Millennials want to be happy and healthy, but they're just so stressed out. Contrary to the typical carefree image of youth, millennials ages 18 to 32 worry about health issues--like getting a serious illness or affording healthcare--as much as baby boomers do, according to a recent study by InVentiv Health companies GSW and Allidura, along with Harris Poll.
Television ads have shown them lounging on a beach, gazing at the view from a mountaintop and watching the view from above a scenic lake. All sans clothing and facing away from the camera. We're talking about Eli Lilly's Cialis bathtub couples, of course. Yet the bathtub couples were not universally well-received at launch, and they've been oft-spoofed since.
Actavis may have lost its court bid to "hard switch" original Namenda users to Namenda XR, but that's all the more reason to continue its aggressive marketing of the newer one-a-day Alzheimer's pill.
When you're targeting an under-the-radar malady that hasn't traditionally been treated with prescription drugs, it's up to marketers to get the word out and deliver on sales. And that's why AstraZeneca and Daiichi Sankyo, whose Movantik launched earlier this year, are bringing a 6-time Olympic medalist on board to talk about opioid-induced constipation (OIC).
Momentum is building at the FDA for an overhaul of DTC advertising. That familiar--and often lampooned--recitation of side effects is looking more and more like an endangered species.
Spring has sprung and so has allergy advertising. Drugmakers blast the airwaves annually as the pollen starts to fly, with the latest sniff and cough relief remedies.
While the list of the top spending DTC ad spenders changes every year, there are always a few certainties and a few surprises.
Afrezza wasn't expected to be the spinach that would give Sanofi's diabetes business instant, superhuman strength. But the inhaled insulin, launched in February under a marketing deal with MannKind, was supposed to help fuel sales growth.